MXPA06012613A - Derivados heterociclicos nitrogenados como moduladores de proteina cinasa y uso para el tratamiento de angiogenesis y cancer. - Google Patents

Derivados heterociclicos nitrogenados como moduladores de proteina cinasa y uso para el tratamiento de angiogenesis y cancer.

Info

Publication number
MXPA06012613A
MXPA06012613A MXPA06012613A MXPA06012613A MXPA06012613A MX PA06012613 A MXPA06012613 A MX PA06012613A MX PA06012613 A MXPA06012613 A MX PA06012613A MX PA06012613 A MXPA06012613 A MX PA06012613A MX PA06012613 A MXPA06012613 A MX PA06012613A
Authority
MX
Mexico
Prior art keywords
compounds
protein kinase
influencing
disease states
angiogenesis
Prior art date
Application number
MXPA06012613A
Other languages
English (en)
Inventor
Joseph L Kim
Stephanie D Geuns-Meyer
Vinod F Patel
Ning Xi
Xiaotian Zhu
Steven Bellon
Yuan Cheng
Brian L Hodous
Stuart C Chaffee
Brian K Albrecht
Victor J Cee
Holly L Deak
Rebecca E Johnson
Hanh Nho Nguyen
Philip R Olivieri
Karina Romero
Paul A Tempest
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MXPA06012613A publication Critical patent/MXPA06012613A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

La presente invencion se refiere a compuestos quimicos que tienen una formula general I (ver formula I) en donde A, B, D, E, G, H1-5 y R1-4 se definen en la presente, e intermediarios sinteticos, los cuales son capaces de modular diversas enzimas de receptor de proteina cinasa y, de tal modo, influenciando diversos estados de enfermedad y condiciones relacionadas con las actividades de estas cinasas. Por ejemplo, los compuestos son capaces de modular enzimas cinasas de tal modo que tienen influencia en los procesos de angiogenesis y tratamiento de enfermedades relacionadas con angiogenesis y otros trastornos proliferativos, que incluyen cancer e inflamacion. La invencion tambien incluye composiciones farmaceuticas, que incluyen los compuestos, y metodos para tratar estados de enfermedad relacionados con la actividad de proteinas cinasas.
MXPA06012613A 2004-05-07 2005-05-09 Derivados heterociclicos nitrogenados como moduladores de proteina cinasa y uso para el tratamiento de angiogenesis y cancer. MXPA06012613A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56919304P 2004-05-07 2004-05-07
PCT/US2005/016346 WO2005113494A2 (en) 2004-05-07 2005-05-09 Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer

Publications (1)

Publication Number Publication Date
MXPA06012613A true MXPA06012613A (es) 2007-01-31

Family

ID=35149480

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06012613A MXPA06012613A (es) 2004-05-07 2005-05-09 Derivados heterociclicos nitrogenados como moduladores de proteina cinasa y uso para el tratamiento de angiogenesis y cancer.

Country Status (8)

Country Link
US (2) US7880000B2 (es)
EP (1) EP1751136B1 (es)
JP (1) JP5097539B2 (es)
AU (1) AU2005245386B2 (es)
CA (1) CA2564355C (es)
ES (1) ES2505090T3 (es)
MX (1) MXPA06012613A (es)
WO (1) WO2005113494A2 (es)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050197371A1 (en) * 2003-11-13 2005-09-08 Ambit Biosciences Corporation Urea derivatives as PDGFR modulators
TW200533357A (en) * 2004-01-08 2005-10-16 Millennium Pharm Inc 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
US7880000B2 (en) * 2004-05-07 2011-02-01 Amgen Inc. Protein kinase modulators and method of use
EP1765327B1 (en) 2004-06-17 2014-08-13 Cytokinetics, Inc. Compounds, compositions and methods
AU2011253934C1 (en) * 2004-06-17 2013-08-22 Cytokinetics, Inc. Substituted urea derivatives for treating cardiac diseases
EP1789390B1 (en) * 2004-09-02 2011-11-09 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
EP1824843A2 (en) * 2004-12-07 2007-08-29 Locus Pharmaceuticals, Inc. Inhibitors of protein kinases
CA2589271A1 (en) * 2004-12-07 2006-06-15 Locus Pharmaceuticals, Inc. Urea inhibitors of map kinases
US7470693B2 (en) * 2005-04-21 2008-12-30 Bristol-Myers Squibb Company Oxalamide derivatives as kinase inhibitors
CA2609126A1 (en) 2005-05-20 2006-11-30 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
US7880004B2 (en) * 2005-09-15 2011-02-01 Bristol-Myers Squibb Company Met kinase inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP1959960B1 (en) 2005-12-15 2013-04-10 Cytokinetics, Inc. Certain chemical entities, compositions and methods
CA2634701C (en) * 2005-12-21 2014-07-29 Decode Genetics Ehf Biaryl substituted nitrogen containing heterocycle inhibitors of lta4h for treating inflammation
US7989461B2 (en) * 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
AU2011211423B2 (en) * 2005-12-23 2014-02-20 Amgen Inc. Nitrogen-containing bicyclic hetroaryl compounds for the treatment of RAF protein kinase-mediated diseases
WO2007081690A2 (en) * 2006-01-04 2007-07-19 Locus Pharmaceuticals, Inc. Inhibitors of protein kinases
GEP20125643B (en) * 2006-01-23 2012-09-25 Amgen Inc Aurora kinase modulators and method of using same
US7560551B2 (en) 2006-01-23 2009-07-14 Amgen Inc. Aurora kinase modulators and method of use
RU2008135690A (ru) * 2006-02-06 2010-03-20 Айрм Ллк (Bm) Соединения и композиции в качестве ингибиторов протеинкиназы
US7868177B2 (en) * 2006-02-24 2011-01-11 Amgen Inc. Multi-cyclic compounds and method of use
EP2032538A2 (en) * 2006-06-08 2009-03-11 Array Biopharma, Inc. Quinoline compounds and methods of use
AU2007257650A1 (en) * 2006-06-15 2007-12-21 Boehringer Ingelheim International Gmbh 2-anilino-4-(heterocyclic)amino-pyrimidines as inhibitors of protein kinase C-alpha
TW200811134A (en) 2006-07-12 2008-03-01 Irm Llc Compounds and compositions as protein kinase inhibitors
FR2904626B1 (fr) 2006-08-03 2008-09-19 Sanofi Aventis Derives de pyrazolo[4,3]thiazole, leur preparation et leur application en therapeutique
US7683060B2 (en) 2006-08-07 2010-03-23 Incyte Corporation Triazolotriazines as kinase inhibitors
EP1894928A1 (en) * 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
GEP20135728B (en) 2006-10-09 2013-01-25 Takeda Pharmaceuticals Co Kinase inhibitors
TW200825054A (en) * 2006-10-18 2008-06-16 Wyeth Corp Quinoline compounds
WO2008057280A1 (en) 2006-10-27 2008-05-15 Amgen Inc. Multi-cyclic compounds and methods of use
CN101535264B (zh) * 2006-11-08 2012-11-28 百时美施贵宝公司 吡啶酮化合物
PL2099447T3 (pl) 2006-11-22 2013-06-28 Incyte Holdings Corp Imidazotriazyny i imidazopirmidyny jako inhibitory kinaz
JP2010514689A (ja) * 2006-12-22 2010-05-06 ノバルティス アーゲー 癌、炎症およびウイルス感染症の処置のためのｃｄｋ阻害剤としてのヘテロアリール−ヘテロアリール化合物
AR065015A1 (es) 2007-01-26 2009-05-13 Smithkline Beecham Corp Derivados de antranilamida, composiciones farmaceuticas que los contienen, y usos para el tratamiento del cancer
US20100130469A1 (en) * 2007-04-06 2010-05-27 Maurice Van Eis 2, 6-naphthridine derivatives
CA2689989A1 (en) * 2007-06-04 2008-12-11 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
WO2008153947A2 (en) * 2007-06-07 2008-12-18 Amgen Inc. Heterocyclic compounds as raf kinase modulators
CN101969972A (zh) * 2007-12-10 2011-02-09 麦特普罗泰欧米克斯有限公司 癌症、血管生成、以及与其相关的炎症通路的取代的1,3-环戊二酮多靶点蛋白激酶调节剂
EP2070929A1 (en) 2007-12-11 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
NZ586630A (en) * 2008-01-23 2011-12-22 Bristol Myers Squibb Co 4-Pyridinone compounds and their use for cancer
JP5693239B2 (ja) 2008-01-23 2015-04-01 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ４−ピリジノン化合物および癌についてのその使用
GB0801416D0 (en) * 2008-01-25 2008-03-05 Piramed Ltd Pharmaceutical compounds
JP5711537B2 (ja) 2008-02-15 2015-05-07 ライジェル ファーマシューティカルズ， インコーポレイテッド ピリミジン−２−アミン化合物およびｊａｋキナーゼの阻害剤としてのその使用
BRPI0912882A2 (pt) 2008-05-21 2017-05-16 Incyte Corp sais de 2-flúor-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamida e processos relacionados à preparação dos mesmos
CA2734172A1 (en) * 2008-08-29 2010-03-04 Genentech, Inc. Diagnostics and treatments for vegf-independent tumors
US8436025B2 (en) 2008-09-19 2013-05-07 CompleGen Partners, Inc. Compounds and methods for PKC theta inhibition
EP2340242A4 (en) * 2008-10-22 2012-04-04 Acucela Inc COMPOUNDS FOR THE TREATMENT OF EYE DISEASES AND DRESSES
KR101052066B1 (ko) 2008-10-24 2011-07-27 한국과학기술연구원 항암 활성을 갖는 신규한 6-(피리딘-3-일)피리미딘 화합물
CN101759683B (zh) * 2008-12-25 2011-12-28 哈尔滨誉衡药业股份有限公司 二氢化茚酰胺化合物制备方法、包含其的药物组合物、及其作为蛋白激酶抑制剂的应用
UY32582A (es) 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
EP2440204B1 (en) 2009-06-12 2013-12-18 Bristol-Myers Squibb Company Nicotinamide compounds useful as kinase modulators
WO2011008788A1 (en) * 2009-07-14 2011-01-20 Dawei Zhang Fluoro-substituted compounds as kinase inhibitors and methods of use thereof
CA2788398C (en) 2010-02-03 2018-02-27 Incyte Corporation Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors
EP2590951B1 (en) 2010-07-09 2015-01-07 Pfizer Limited Benzenesulfonamides useful as sodium channel inhibitors
PL2647637T3 (pl) * 2010-12-02 2016-06-30 Medpacto Inc Pochodna purynylopirydynyloamino-2,4-dlfluorofenylo-sulfonamidu, jej farmaceutycznie dopuszczalna sól, sposób jej wytwarzania oraz zawierająca ją jako składnik aktywny kompozycja farmaceutyczna o aktywności hamującej kinazę Raf
CN103018349B (zh) * 2011-09-22 2015-04-08 北京美迪康信医药科技有限公司 一种二氢化茚酰胺化合物的检测分析方法
RU2486180C1 (ru) * 2011-11-02 2013-06-27 Общество с ограниченной ответственностью "ТехноХим" (ООО "ТехноХим") Способ получения 2-ариламино-4-гетарилпиримидинов
WO2013083604A1 (en) * 2011-12-09 2013-06-13 Chiesi Farmaceutici S.P.A. Kinase inhibitors
KR101415742B1 (ko) * 2011-12-21 2014-07-04 영남대학교 산학협력단 6―아미노피리딘―3―올 유도체 또는 이의 약제학적 허용가능한 염 및 이를 유효성분으로 함유하는 혈관신생으로 인한 질환의 예방 또는 치료용 약학조성물
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
CN102807558A (zh) * 2012-08-29 2012-12-05 浙江大德药业集团有限公司 作为蛋白激酶抑制剂的含氟二氢化茚酰胺类化合物
US10301264B2 (en) * 2012-10-17 2019-05-28 The University Of Nottingham Compounds useful for treating ocular neovasculan
KR20140092696A (ko) * 2013-01-16 2014-07-24 주식회사유한양행 신규의 페닐에티닐 벤즈아마이드 글루코키나제 활성화제 및 그의 제조방법
CN105188694B (zh) 2013-03-15 2018-07-31 卓莫赛尔公司 用于治疗疼痛的钠通道调节剂
CU24334B1 (es) 2013-06-27 2018-04-03 Pfizer Piridin-2 que contienen il-4-derivados sustituidos de 1-diazino fenilo útiles como ligandos de dopamina
BR112016005271A2 (pt) 2013-09-10 2020-05-12 Chromocell Corporation Moduladores de canais de sódio para o tratamento da dor e do diabetes
EP3083604A1 (en) * 2013-12-20 2016-10-26 Respivert Limited Urea derivatives useful as kinase inhibitors
CN107002119A (zh) 2014-03-24 2017-08-01 豪夫迈·罗氏有限公司 使用c‑met拮抗剂的癌症治疗及前者与hgf表达的关联
CN104045632B (zh) * 2014-06-03 2016-09-07 辽宁大学 抗肿瘤药物苯并二氢吡喃（噻喃）酰胺类化合物及其药学上可接受的盐及制备方法和应用
CN107257793A (zh) * 2015-01-20 2017-10-17 梅里亚股份有限公司 抗蠕虫化合物、组合物及其使用方法
EP3347097B1 (en) * 2015-09-11 2021-02-24 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
BR112018004447A2 (pt) * 2015-09-18 2018-09-25 Kaken Pharmaceutical Co., Ltd. derivado de biarila e medicamento contendo o mesmo
TW201838981A (zh) * 2017-03-17 2018-11-01 美商建南德克公司 嘧啶基-吡啶氧基-萘基化合物以及治療ire1相關之疾病及病症的方法
MX2020002611A (es) * 2017-09-07 2020-07-13 Univ Res Inst Inc Augusta Activador especifico de akt3 y usos del mismo.
WO2020047518A1 (en) * 2018-08-30 2020-03-05 The Regents Of The University Of California Ire1 kinase inhibitors and uses thereof
JP7320600B2 (ja) * 2018-09-12 2023-08-03 ジェネンテック， インコーポレイテッド フェノキシ－ピリジル－ピリミジン化合物及び使用方法
US20220048888A1 (en) * 2018-09-12 2022-02-17 Genentech, Inc. Pyrimidinyl-heteroaryloxy-naphthyl compounds and methods of use
CN113508115A (zh) 2019-01-03 2021-10-15 基因泰克公司 吡啶并嘧啶酮和蝶啶酮化合物作为需要酶i(ire i α)的内切核糖核酸酶肌醇的抑制剂用于治疗癌症疾病
KR20210151051A (ko) * 2019-02-14 2021-12-13 브리진 바이오사이언시스, 인코포레이티드 암 치료를 위한 fgfr 억제제
AR118119A1 (es) 2019-02-18 2021-09-22 Genentech Inc Compuestos de pirido-pirimidinilo y métodos de uso
CN114302877A (zh) 2019-06-11 2022-04-08 基因泰克公司 喹唑啉基化合物及使用方法
EP4025570A4 (en) * 2019-09-06 2022-11-02 ONO Pharmaceutical Co., Ltd. HYDANTOINDIVATIVES
AU2021214767A1 (en) 2020-01-29 2022-07-28 Foghorn Therapeutics Inc. Compounds and uses thereof
JP2023536139A (ja) * 2020-07-29 2023-08-23 フォグホーン セラピューティクス インコーポレイテッド 化合物及びその使用
US11787800B2 (en) 2020-07-29 2023-10-17 Foghorn Therapeutics Inc. BRD9 degraders and uses thereof
EP3995494A1 (en) * 2020-11-06 2022-05-11 Eberhard Karls Universität Tübingen Protein-protein interaction modulators of aurora kinase a and their use in the prevention and/or treatment of cancer
US11884649B2 (en) * 2020-11-13 2024-01-30 The Regents Of The University Of California IRE1α inhibitors and uses thereof
WO2022199654A1 (en) * 2021-03-24 2022-09-29 Chengdu Anticancer Bioscience, Ltd. Heteroaryl-heteroaryl-o-phenyl compounds, compositions and methods of treating cancer disorders
WO2023283263A1 (en) 2021-07-06 2023-01-12 Foghorn Therapeutics Inc. Citrate salt, pharmaceutical compositions, and methods of making and using the same
WO2023081854A1 (en) * 2021-11-05 2023-05-11 Georgiamune Llc Akt3 modulators
WO2023183444A1 (en) * 2022-03-24 2023-09-28 Vibliome Therapeutics, Llc Modulators of protein kinases

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA80492B (en) * 1979-02-07 1981-01-28 Hoffmann La Roche Benzazepine derivatives
NZ192803A (en) * 1979-02-07 1984-08-24 Hoffmann La Roche Pyrimido-2-benzazepines and pharmaceutical compositions
US4318854A (en) 1979-02-07 1982-03-09 Hoffmann-La Roche Inc. Intermediates in the production of 2-benzazepines
JPS6094964A (ja) * 1983-10-31 1985-05-28 Banyu Pharmaceut Co Ltd 置換−２−ピリドン誘導体
US5049570A (en) * 1990-01-23 1991-09-17 Du Pont Merck Pharmaceutical Company Pyridylphenyl nitrogen heterocycle-substituted carbinols and derivatives thereof with anti-inflammatory activity
US5506227A (en) 1992-04-13 1996-04-09 Merck Frosst Canada, Inc. Pyridine-substituted benzyl alcohols as leukotriene antagonists
US6143764A (en) 1995-11-07 2000-11-07 Kirin Beer Kabushiki Kaisha Quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation and pharmaceutical compositions containing the same
US6060491A (en) 1997-06-19 2000-05-09 Dupont Pharmaceuticals 6-membered aromatics as factor Xa inhibitors
JPH11209350A (ja) 1998-01-26 1999-08-03 Eisai Co Ltd 含窒素複素環誘導体およびその医薬
PL205557B1 (pl) 1999-02-10 2010-05-31 Astrazeneca Ab Pochodne indolu
EP1218360B1 (en) * 1999-10-07 2008-05-28 Amgen Inc., Triazine kinase inhibitors
EP1313713B1 (en) 2000-08-08 2008-06-11 Ortho-McNeil Pharmaceutical, Inc. 4-pyrimidinamine derivatives, pharmaceutical compositions and related methods
US20030008841A1 (en) * 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
DE60126997T2 (de) 2000-10-20 2007-10-25 Eisai R&D Management Co., Ltd. Stickstoff-enthaltende aromatische ringverbindungen zur behandlung von tumorerkrankungen
ES2272567T3 (es) * 2000-12-21 2007-05-01 Vertex Pharmaceuticals Incorporated Compuestos de pirazol utiles como inhibidores de proteina quinasas.
DE60239097D1 (de) * 2001-03-02 2011-03-17 Gpc Biotech Ag Drei-hybrid-assaysystem
US6864255B2 (en) 2001-04-11 2005-03-08 Amgen Inc. Substituted triazinyl amide derivatives and methods of use
CA2443697A1 (en) 2001-04-13 2002-10-24 Pier F. Cirillo 1,4-disubstituted benzo-fused compounds
EP2258366B1 (en) 2001-06-22 2013-04-03 Kirin Pharma Kabushiki Kaisha Quinoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same
JPWO2003024913A1 (ja) * 2001-09-17 2004-12-24 第一サントリーファーマ株式会社 ＮＦ−κＢ阻害作用を有する置換安息香酸誘導体
BR0213792A (pt) 2001-11-01 2004-12-07 Janssen Pharmaceutica Nv Heteroaril aminas como inibidores de glicogênio sintase cinase 3beta (inibidores de gsk3)
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
US20040039601A1 (en) * 2002-08-23 2004-02-26 Anderson Corey D. Virtual file cabinet including health information method and apparatus
JP4895806B2 (ja) 2003-04-09 2012-03-14 エクセリクシス， インク． Ｔｉｅ−２モジュレータと使用方法
WO2005026129A1 (en) 2003-09-15 2005-03-24 Gpc Biotech Ag Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
CN100412066C (zh) 2003-09-30 2008-08-20 Irm责任有限公司 用作蛋白激酶抑制剂的化合物和组合物
US7608639B2 (en) * 2003-10-14 2009-10-27 Eli Lilly And Company Phenoxyether derivatives as PPAR modulators
US7880000B2 (en) * 2004-05-07 2011-02-01 Amgen Inc. Protein kinase modulators and method of use
US7989461B2 (en) * 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
US7560551B2 (en) 2006-01-23 2009-07-14 Amgen Inc. Aurora kinase modulators and method of use
US7868177B2 (en) * 2006-02-24 2011-01-11 Amgen Inc. Multi-cyclic compounds and method of use

Also Published As

Publication number Publication date
AU2005245386A1 (en) 2005-12-01
CA2564355A1 (en) 2005-12-01
EP1751136A2 (en) 2007-02-14
JP5097539B2 (ja) 2012-12-12
CA2564355C (en) 2012-07-03
AU2005245386B2 (en) 2008-11-27
EP1751136B1 (en) 2014-07-02
US8476434B2 (en) 2013-07-02
ES2505090T3 (es) 2014-10-09
JP2007536280A (ja) 2007-12-13
US20060009453A1 (en) 2006-01-12
US7880000B2 (en) 2011-02-01
WO2005113494A3 (en) 2006-03-16
US20110201602A1 (en) 2011-08-18
WO2005113494A2 (en) 2005-12-01

Similar Documents

Publication Publication Date Title
MXPA06012613A (es) Derivados heterociclicos nitrogenados como moduladores de proteina cinasa y uso para el tratamiento de angiogenesis y cancer.
ATE478861T1 (de) Multizyklische verbindung und verwendungsverfahren
WO2008124083A3 (en) Aurora kinase modulators and method of use
MY161884A (en) Aurora kinase modulators and method of use
MX2010010151A (es) Moduladores de cinasa aurora y metodo de uso.
MX2021007158A (es) Heteroarilamidas utiles como inhibidores de kif18a.
MX2021007157A (es) Heteroarilamidas utiles como inhibidores de kif18a.
TW200700068A (en) Phthalazine, aza-and diaza-phthalazine compounds and methods of use
EA201100461A1 (ru) Спиро-трициклические соединения как модуляторы бета-секретазы и способы их использования
MX2022001302A (es) Inhibidores de kif18a.
BRPI0409173A (pt) compostos e composições como inibidores de proteìna quinase
DK1438310T3 (da) Beta-carbolin-derivater som PTP-inhibitorer
NO20090581L (no) Hydroksylerte og metoksylerte syklopenta[D]pyrimidiner som AKT-proteinkinaseinhibitorer
EA200900779A1 (ru) Производные дигидропиридина, полезные как ингибиторы протеинкиназы
WO2006039718A3 (en) Aryl nitrogen-containing bicyclic compounds and their use as kinase inhibitors
MX2009012608A (es) Compuestos de hidroxietil amina substituidos como moduladores de beta-secretasa y metodos de uso.
MX2022001181A (es) Inhibidores de kif18a.
NO20062884L (no) AKT-proteinkinaseinhibitorer
EA200301232A1 (ru) Новые соединения арилсульфонамида и их применение для лечения ожирения, диабета типа ii и нарушений центральной нервной системы
TW200732339A (en) Nitrogen-containing bicyclic heteroaryl compounds and methods of use
TW200519096A (en) Quinazoline analogs as receptor tyrosine kinase inhibitors
WO2006058869A8 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
MX2012010657A (es) Compuestos de espiro amino-dihidrooxazina y amino-dihidrotiazina como moduladores de beta-secretasa y su uso medico.
MX2009003981A (es) Agentes moduladores del receptor de calcio.
BRPI0418120A (pt) composto, composição farmacêutica, e, métodos para tratar um distúrbio, uma doença ou distúrbio, e para tratar mieloma múltiplo ou leucemia

Legal Events

Date Code Title Description
FG Grant or registration